1. Home
  2. PZG vs LUNG Comparison

PZG vs LUNG Comparison

Compare PZG & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Paramount Gold Nevada Corp.

PZG

Paramount Gold Nevada Corp.

N/A

Current Price

$1.23

Market Cap

113.8M

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

N/A

Current Price

$1.92

Market Cap

97.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PZG
LUNG
Founded
1992
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Industrial Specialties
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
113.8M
97.1M
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
PZG
LUNG
Price
$1.23
$1.92
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $3.40
AVG Volume (30 Days)
★ 265.1K
255.6K
Earning Date
09-17-2026
10-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 7.64
EPS
★ N/A
N/A
Revenue
$330,259.00
★ $90,497,000.00
Revenue This Year
N/A
$0.06
Revenue Next Year
N/A
$8.58
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 8.01
52 Week Low
$0.95
$1.13
52 Week High
$2.70
$2.89

Technical Indicators

Market Signals
Indicator
PZG
LUNG
Relative Strength Index (RSI) 36.94 44.84
Support Level $1.07 $1.20
Resistance Level $1.26 $2.12
Average True Range (ATR) 0.06 0.10
MACD -0.01 -0.01
Stochastic Oscillator 15.00 36.65

Price Performance

Historical Comparison
PZG
LUNG

About PZG Paramount Gold Nevada Corp.

Paramount Gold Nevada Corp is an exploration-stage mining company. Together with its subsidiaries, the company is engaged in the business of acquiring, exploring, and developing precious metal projects in the United States. Also, it explores for gold and silver. The company enhances the value of projects by implementing exploration and engineering programs that are likely to expand and upgrade known mineralized material to reserves. Its projects include sleeper gold, grassy mountain gold and Bald Peak Project.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). solution, which is comprised of the Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System), and the LungTraX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The majority of the company's revenue is generated from the provision of cloud hosting and management services. The company geographically, operates in the USA, the EMEA, the Asia Pacific, and other international regions, the majority of revenue from USA.

Share on Social Networks: